2-甲基-3-氧代-戊酸 | 14925-93-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 2-甲基-3-氧代-戊酸
• 英文名称: 2-methyl-3-oxopentanoic acid
• CAS: 14925-93-0
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: QTLYPQZWYOHATR-UHFFFAOYSA-N

物化性质

• 沸点：
  236.3±23.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 溶解度：
  30 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  2-甲基-3-氧代-戊酸 在 草酰氯 、 硫酸 、 乙酸酐 、 二甲基亚砜 、 三乙胺 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6-(1-methyl-2-oxopropyl)-2,2,5-trimethyl-4H-1,3-dioxin-4-one
  参考文献：
  名称：

  Mechanism and Stereospecificity of a Fully Saturating Polyketide Synthase Module: Nanchangmycin Synthase Module 2 and Its Dehydratase Domain

  摘要：

  Recombinant nanchangmycin synthase module 2 (NANS module 2), with the thioesterase domain from the 6-deoxyerythronolide B synthase (DEBS TE) appended to the C-terminus, was cloned and expressed in Escherichia coli. Incubation of NANS module 2+TE with (+/-)-2-methyl-3-keto-butyryl-N-acetylcysteamine thioester (1), the SNAC analog of the natural ACP-bound substrate, with methylmalonyl-CoA (MM-CoA) in the absence of NADPH gave 3,5,6-trimethy1-4-hydroxypyrone (2), identified by direct comparison with synthetic 2 by radio-TLC-phosphorimaging and LC-ESI(+)-MS-MS. The reaction showed K(cat) 0.5 +/- 0.1 min(-1) and K(m)(1) 19 +/- 5 mM at 0.5 mM MM-CoA and k(cat)(app) 0.26 +/- 0.02 min(-1) and K(m)(MM-CoA) 0.11 +/- 0.02 mM at 8 mM 1. Incubation in the presence of NADPH generated the fully saturated triketide chain elongation product as a 5:3 mixture of (2S,4R)-2,4-dimethy1-5-ketohexanoic acid (3a) and the diastereomeric (2S, 4S)-3b. The structure and stereochemistry of each product was established by comparison with synthetic 3a and 3b by a combination of radio-TLC-phosphorimaging and LC-ESI(-)-MS-MS, as well as chiral capillary GC-MS analysis of the corresponding methyl esters 3a-Me and 3b-Me. The recombinant dehydratase domain from NANS module 2, NANS DH2, was shown to catalyze the formation of an (E)-double bond by syndehydration of the ACP-bound substrate anti-(2R,3R,4S,5R)-2,4-dimethyl-3,5-dihydroxyheptanoyl-ACP6 (4), generated in situ by incubation of (2S,3R)-2-methyl-3-hydroxypentanoyl-SNAC (5), methylmalonyl-CoA, and NADPH with the recombinant [KS6][AT6] didomain and ACP6 from DEBS module 6 along with the ketoreductase from the tylactone synthase module 1 (TYLS KR1). These results also indirectly establish the stereochemistry of the reactions catalyzed by the KR and enoylreductase (ER) domains of NANS module 2.

  DOI：

  10.1021/ja1073432
• 作为产物：
  描述：

  2-methyl-3-oxovaleric acid N-acetylcysteamine thioester 在 phosphate buffer 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 生成 2-甲基-3-氧代-戊酸
  参考文献：
  名称：

  来自pimaricin和红霉素生物合成途径的硫酯酶结构域可以催化简单的硫酯底物的水解。

  摘要：

  来自pimaricin和6-deoxyerythronolide B生物合成途径的重组聚酮化合物合酶硫酯酶结构域催化许多简单的N-乙酰半胱胺硫酯衍生物的水解。这项研究表明，与非核糖体肽合酶硫酯酶结构域对底物负载具有很高的特异性相比，硫酯酶在酰基酶中间体的形成中对底物的选择性不是很高。该观察结果对生产聚酮化合物产品的生物合成途径的工程设计具有重要意义。

  DOI：

  10.1016/j.bmcl.2007.03.060

文献信息

• Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias
  申请人：Bark Thomas

  公开号：US20130109662A1

  公开（公告）日：2013-05-02

  The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

  这项发明涉及铁（III）配合物和包括它们的药物组合物，用作药物，特别是用于治疗和/或预防缺铁症状和缺铁性贫血。
• Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
  申请人：Palani Anandan

  公开号：US20060264489A1

  公开（公告）日：2006-11-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

  具有通式（I）的一种化合物： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，其中： Q选自以下群组： 和 L选自以下群组： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾患或症状。
• [EN] 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] KÉTOLIDES À 14 CHAÎNONS ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：HARVARD COLLEGE

  公开号：WO2016057798A1

  公开（公告）日：2016-04-14

  Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.

  本文提供了一种制备新的14元环酮类化合物的方法，通过将东半部分和西半部分偶联，然后进行大环化，以及可选的官能化。还提供了合成这些酮类化合物的中间体，包括东部和西部部分。还提供了使用这些酮类化合物治疗传染病和炎症性疾病的药物组合物和方法。
• ketene bis(trialkylsilyl) acetals: synthesis, pyrolysis and spectral studies
  作者：C. Ainsworth、Yu-Neng Kuo

  DOI：10.1016/s0022-328x(00)90476-5

  日期：1972.12

  methods are described for the preparation of alkyl, dialkyl, aryl and diaryl ketene bis(trialkylsilyl)acetals. One is by reaction of αmetalated trimethylsilyl carboxylates with trimethylchlorosilane (TMCS) and the otehr is by inteaction of dianions of carboxylic acids and TMCS. The dianion of cyclopropane carboxylic acid and TMCS gave C-silated ester in 90% yield. Pyrolysis of diphenyl ketene bis(trialkylsilyl)

  描述了两种高产率的合成方法，用于制备烷基，二烷基，芳基和二芳基乙烯酮双（三烷基甲硅烷基）缩醛。一种是通过α金属化的三甲基甲硅烷基羧酸盐与三甲基氯硅烷（TMCS）的反应，而另一种是通过羧酸与TMCS的二价阴离子的相互键合。环丙烷羧酸和TMCS的二价阴离子以90％的收率得到C-硅酸酯。交叉实验表明，二苯基乙烯酮双（三烷基甲硅烷基）缩醛热解为二苯基乙烯酮和双（三烷基甲硅烷基）醚在分子间进行。单取代的和二烷基酮烯（三甲基甲硅烷基）缩醛的热解得到了酮烯-酮缩醛的加成产物（III），其在溶剂分解时以高收率提供了β-酮酸。给出了许多化合物的NMR和质谱数据。
• Compounds for the treatment of pain
  申请人：——

  公开号：US20030176314A1

  公开（公告）日：2003-09-18

  This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.

  这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法，包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。